| Literature DB >> 34070646 |
Mizraín Solares-Briones1, Guadalupe Coyote-Dotor1, José C Páez-Franco1, Miriam R Zermeño-Ortega2, Carmen Myriam de la O Contreras2, Daniel Canseco-González3, Alcives Avila-Sorrosa4, David Morales-Morales5, Juan M Germán-Acacio1.
Abstract
Mechanochemistry is considered an alternative attractive greener approach to prepare diverse molecular compounds and has become an important synthetic tool in different fields (e.g., physics, chemistry, and material science) since is considered an ecofriendly procedure that can be carried out under solvent free conditions or in the presence of minimal quantities of solvent (catalytic amounts). Being able to substitute, in many cases, classical solution reactions often requiring significant amounts of solvents. These sustainable methods have had an enormous impact on a great variety of chemistry fields, including catalysis, organic synthesis, metal complexes formation, preparation of multicomponent pharmaceutical solid forms, etc. In this sense, we are interested in highlighting the advantages of mechanochemical methods on the obtaining of pharmaceutical cocrystals. Hence, in this review, we describe and discuss the relevance of mechanochemical procedures in the formation of multicomponent solid forms focusing on pharmaceutical cocrystals. Additionally, at the end of this paper, we collect a chronological survey of the most representative scientific papers reporting the mechanochemical synthesis of cocrystals.Entities:
Keywords: green reactions; mechanochemistry; pharmaceutical cocrystals
Year: 2021 PMID: 34070646 PMCID: PMC8228148 DOI: 10.3390/pharmaceutics13060790
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Classification of an API depending on its scale range-order periodicity and composition. Adapted with permission from [15], Elsevier, 2017.
Figure 2Symbolic representations of the different solid state-chemistry synthetic methods. Adapted with permission from [101], Royal Society of Chemistry, 2019.
Figure 3Different branches derived from the mechanochemistry. Adapted with permission from [80], Royal Society of Chemistry, 2014. SDG: solvent drop-grinding; LAG: liquid-assisted grinding; MOFs: metal-organic frameworks.
Scheme 1Pd-catalyzed C-C coupling reactions (Suzuki–Miyaura).
Figure 4Classification of solid–solid reactions: (a) intrasolid and (b) intersolid. Adapted with permission from [189], Wiley, 2004.
Figure 5Sheets of caf:glu (1:1) ribbons. (a) Form I and (b) Form II. Stacked ribbons of caf:glu (1:1): (c) Form I and (d) Form II. CSD refcodes: Form I; EXUQUJ (P21/c) and Form II; EXUQUJ01 (Pī).
Figure 6Sheets of caf:ca (1:1) ribbons. (a) Form I and (b) Form II. CSD refcodes: Form I; KIGKER (Pī) [216] and Form II; KIGKER01 (P21/c).
Figure 7ILs employed in ILAG experiments.
Figure 8Schematic representation of cocrystal formation mechanism applying grinding/milling in a binary system. Adapted with permission from [117], American Chemical Society, 2009.
Figure 9Schematic representation of the different solid forms in the cocrystal system nic:adi. These processes can be controlled by the choice of milling assembly. Adapted with permission from [229], Royal Society of Chemistry, 2020.
Figure 10Schematic representation of the two proposed mechanisms behind the formation of HIMO:TBA.
Figure 11Schematic representation of the formation of multicomponent salt or cocrystal or ionic cocrystal.
Figure 12Formation of different multicomponent solid forms (β-ala + DL-ta; 1:1) depending on the synthetic method used: (a) cocrystal (plane bc; CSD refcode: VELBIA) and (b) multicomponent salt (plane bc; CSD refcode: VELBIA01).
Figure 13Schematic representation of binary phase diagrams (components A + B). (a) Solid eutectic mixture; TE: eutectic temperature. (b) Cocrystal formation; TE1 and TE2: eutectic temperatures 1 and 2. (c) Solid solution formation. (d) Physical mixture. Adapted with permission from [48], MDPI, 2018.
Figure 14Cocrystal formation of cbz:nic 1:1 (CSD refcode: UNEZES; P21/n) using RAM.
Chronological summary of the most representative publications related with the formation of pharmaceutical cocrystals or multicomponent salts by mechanochemical procedures.
| API or NP + Coformer or API + API | Year of the Paper | Type of Grinding or Method of Synthesis and Characterization | Type of Multicomponent Form | Reference |
|---|---|---|---|---|
| Adenine + Thymine | 1993 | NG/slow evaporation | Cocrystal | [ |
| Sulfadimidine + 8 diverse Carboxylic acids coformers | 1995 | NG | Cocrystal | [ |
| Caffeine + Glutaric acid | 2004 | SDG | Cocrystal | [ |
| Caffeine or Theophylline + chiral or racemic forms D,L-tartaric acid | 2006 | LAG | Cocrystal | [ |
| Ternary system Caffeine + Succinic acid + diverse solvent guest | 2006 | NG/LAG/slow evaporation | Cocrystal solvent | [ |
| Caffeine or Theophylline + citric acid | 2007 | NG/LAG | Cocrystal | [ |
| Theophylline + 1,7-Heptanediamine | 2007 | NG | Salt-Cocrystal Continuum | [ |
| Nicotinamide + Mandelic acid or Ibuprofen | 2007 | NG/LAG | Cocrystal | [ |
| Carbamazepine + diverse coformers | 2009 | SDG/slow evaporation | Cocrystal | [ |
| Theophylline or Caffeine + L-Malic or L-Tartaric acid | 2009 | LAG/sonochemical reactions | Cocrystal | [ |
| Meloxicam + Succinic acid or Maleic acid | 2009 | SDG | Cocrystal | [ |
| Nicotinamide + 10 diverse dicarboxylic acids coformers | 2009 | Melt/NG/LAG/slow evaporation | Cocrystal | [ |
| Paracetamol + 13 diverse coformers | 2009 | NG/LAG | Cocrystal | [ |
| 2-Chloro-4-nitrobenzoic acid + Nicotinamide | 2010 | LAG/slow evaporation | Cocrystal | [ |
| Indomethacin + 30 diverse coformers | 2011 | LAG/Prediction of cocrystal formation employing Hansen solubility parameter | Cocrystal | [ |
| Piracetam + Citric acid or Tartaric acid | 2011 | NG/LAG | Cocrystal | [ |
| Nicotinamide + five Fenamic acid derivatives | 2011 | LAG/liquid assisted sonication/slow evaporation | Cocrystal | [ |
| Curcumin + Resorcinol or Pyrogallol | 2011 | LAG | Cocrystal | [ |
| Prulifloxacin + Salicylic acid | 2011 | Kneading | Cocrystal | [ |
| Furosemide + 8 diverse coformers | 2012 | LAG | Cocrystal | [ |
| Acetazolamide + diverse carboxilic acids or amide derivatives coformers | 2012 | LAG | Cocrystal | [ |
| Indomethacin + Saccharin | 2012 | LAG | Cocrystal | [ |
| Nitrofurantoin + 4-Hydroxybenzoic acid or Nicotinamide or L-Proline or Vanillic acid | 2012 | LAG | Cocrystal | [ |
| Piroxicam + 20 different carboxylic acids | 2012 | LAG/fast cooling and slow cooling of a hot saturated solution/precipitation with an antisolvent/slow evaporation/melting | Cocrystal/cocrystal hydrate/coamorphous | [ |
| Meloxicam + diverse carboxylic acids | 2012 | SDG | Cocrystal | [ |
| DL-Malic acid + L-Tartaric acid and L-Malic acid + DL-Tartaric acid | 2012 | LAG | Cocrystal | [ |
| Andrographolide (NP) + Vanilin or Vanillic acid or Salicylic acid or Guaiacol | 2013 | LAG | Cocrystal | [ |
| α- or γ-Glycine + 7 carboxylic acids coformers | 2013 | NG/spray drying/fast and slow anti-solvent techniques | Cocrystal/multicomponent salt | [ |
| Racemic Praziquantel + diverse aliphatic dicarboxylic acids coformers | 2013 | LAG/slurry method | Cocrystal | [ |
| Carbamazepine + Saccharin and Nicotinamide + Suberic acid | 2013 | LAG | Cocrystal | [ |
| L-Serine (anhydrous or monohydrate) + Oxalic acid (anhydrous or dihydrate) | 2014 | NG/LAG/slow evaporation/precipitation on antisolvent crystallization | Multicomponent salt/multicomponent salt hydrate/multicomponent salt polymorph | [ |
| Trospium chloride + diverse carboxylic acid coformers | 2014 | NG/LAG/slurry method/slow evaporation | Cocrystal | [ |
| AMG 517 + Sorbic acid | 2014 | Ball-milling/TSE | Cocrystal | [ |
| Caffeine + Anthranilic acid | 2014 | LAG | Cocrystal polymorph | [ |
| Lenalidomide + urea or 3,5-Dihydroxybenzoic acid (1:1 and 1:2:1 monohydrate) | 2014 | LAG | Cocrystal | [ |
| Ezetimibe + Methyl paraben | 2014 | LAG/slow evaporation | Cocrystal | [ |
| α-Glycine + β-Malonic acid | 2014 | NG/LAG/Impact treatment/shear treatment/vibratory treatment | Multicomponent salt | [ |
| Stanozolol + Malonic acid or D-Phenyllactic acid or 6-Hydroxy-2-Naphthoic Acid | 2014 | LAG | Cocrystal | [ |
| Caffeine + Citric acid or Anthranilic acid and Phenazine + Mesaconic acid | 2015 | LAG/POLAG | Cocrystal | [ |
| Pyrazinamide + | 2015 | LAG | Stoichiometric cocrystals | [ |
| Theobromine + Oxalic acid | 2015 | NG/structure solved based on the powder X-ray data/in situ using synchrotron powder X-ray diffraction | Cocrystal | [ |
| Theophylline + 4-Aminosalicylic acid or 4-Aminobenzoic acid | 2015 | LAG/slow evaporation | Cocrystal | [ |
| Pyrimidin-2-amine + Glutaric acid | 2015 | NG/slow evaporation | Cocrystal/salt-cocrystal continuum | [ |
| Theophylline + Benzoic acid | 2015 | NG/In Situ investigations of milling reactions using combined powder X-ray Diffraction and Raman spectroscopy | Cocrystal | [ |
| Anthranilic acid + Carbamazepine or Salicylic acid or Theophylline and Salicylic acid + theobromine | 2015 | NG/LAG/slurry methods/competitive milling reactions | Cocrystal | [ |
| Pentoxifylline + diverse carboxylic acid derivatives or Furosemide or L-Ascorbic acid | 2015 | NG/LAG/ | Cocrystal | [ |
| Triamterene + DL-Mandelic acid or Saccharin | 2015 | LAG/slurry method | Cocrystal | [ |
| Theophylline + | 2015 | LAG/slow evaporation | Cocrystal | [ |
| Adefovir Dipivoxil + Glutaric acid | 2015 | LAG | Cocrystal | [ |
| Resveratrol + 4-Aminobenzamide or Isoniazid | 2016 | LAG/rapid solvent removal | Cocrystal | [ |
| Ethionamide + Oxalic acid or Glutaric acid or Adipic acid or Sebacic acid or Fumaric acid | 2016 | LAG | Cocrystal/multicomponent salt | [ |
| Piroxicam + Saccharin | 2016 | NG/LAG/slow evaporation | Cocrystal | [ |
| Theophylline + Benzamide | 2016 | LAG/solvent screening/in situ synchrotron powder X-ray diffraction | Cocrystal/Cocrystal polymorph | [ |
| Glicazide + Malic acid or Succinic acid | 2016 | LAG | Cocrystal | [ |
| Ibuprofen + Nicotinamide | 2016 | NG/in situ Raman spectroscopy | Cocrystal | [ |
| Simvastatin + Malic acid | 2016 | LAG | Cocrystal | [ |
| Theophylline + Benzamide | 2016 | NG/synchrotron X-ray powder diffraction data | Cocrystal | [ |
| Meloxicam + Acetylendicarboxylic acid | 2016 | LAG/slow evaporation | Cocrystal | [ |
| Theophylline + Benzamide or Benzoic acid or Isonicotinamide | 2016 | NG/Competitive Cocrystal Reactions/in situ powder X-ray diffraction | Cocrystal | [ |
| Pyrazinamide + Oxalic acid | 2016 | NG/LAG/in situ using combined synchrotron Powder X-ray Diffraction and Raman | Cocrystal | [ |
| 5-Fluorouracil + 3-Hydroxybenzoic acid or 4-Aminobenzoic acid or Cinnamic acid | 2016 | LAG/slurry method | Cocrystal | [ |
| Lamotrigine + 4,4′-Bipyridine or 2,2′-Bipyridine | 2017 | LAG | Cocrystal | [ |
| Aripiprazole + Orcinol | 2017 | LAG | Cocrystal | [ |
| Hydrochlorothiazide + Piperazine or Tetramethylpyrazine or Picolinamide or Isoniazid or Malonamide or Isonicotinic acid | 2017 | NG/LAG | Cocrystal | [ |
| Glicazide + Sebacic acid or α-Hydroxyacetic acid | 2017 | LAG | Cocrystal | [ |
| Praziquantel + Citric acid or Malic acid or Salicylic acid or Tartaric acid | 2017 | NG/LAG | Cocrystal | [ |
| γ-Glycine + Oxalic acid dihydrate | 2017 | NG/Real-time in situ X-ray powder diffraction | Multicomponent salt | [ |
| Mycophenolic acid + Isonicotinamide or Minoxidil or 2,2′-Dipyridylamine | 2017 | LAG/slow evaporation | Cocrystal | [ |
| Gliclazide + Catechol or Resorcinol or | 2017 | LAG/slow evaporation | Cocrystal/multicomponent salt | [ |
| Pyrazinamide + Malonic acid | 2017 | NG/LAG/slurry methods/In situ Powder X-ray Diffraction | Cocrystal polymorph | [ |
| Carbamazepine + | 2017 | LAG/slurry methods/slow evaporation | Cocrystal | [ |
| Theobromine + Oxalic acid and Pyrazinamide + Oxalic acid | 2017 | NG/LAG/in situ Raman experiments | Cocrystal | [ |
| Felodipine + Imidazole | 2017 | LAG/in situ Raman experiments | Cocrystal | [ |
| Metformin hydrochloride + Dehydrated disodium succinate | 2017 | NG/melting/slow evaporation | Multicomponent salt | [ |
| Chlorothiazide + 13 diverse coformers | 2017 | LAG/slow evaporation | Cocrystal/multicomponent salt | [ |
| 11-Azaartemisinin + 13 diverse carboxylic acids coformers | 2018 | LAG | Cocrystal | [ |
| Fluoxetine·HCl + Fumaric acid or Benzoic acid or Succinic acid | 2018 | NG/LAG/solvothermal synthesis/slow evaporation | Cocrystal | [ |
| 11-Azaartemisinin + | 2018 | LAG | Cocrystal | [ |
| Seselin (NP) + Thiourea | 2018 | LAG/slow evaporation | Cocrystal | [ |
| β-Alanine + DL-Tartaric acid | 2018 | NG/LAG | Cocrystal/multicomponent salt | [ |
| Naproxen + Proline | 2018 | LAG | Cocrystal polymorph/cocrystal hydrate/cocrystal solvate | [ |
| Caffeine + Dapsone | 2018 | Slow evaporation/LAG/spray drying | Cocrystal | [ |
| Theophylline + Aspirin | 2018 | NG/LAG/slurry method/ternary phase diagram | Multidrug cocrystal | [ |
| Caffeine + Citric acid or Glutaric acid | 2018 | ILAG | Cocrystal polymorph | [ |
| Glipizide + Glycolic acid | 2018 | NG/LAG/slurry method/slow evaporation | Cocrystal | [ |
| Theophylline + Benzamide | 2018 | LAG | Cocrystal polymorph | [ |
| Diclofenac acid + L-Proline | 2018 | NG/LAG | Cocrystal | [ |
| Pefloxacin + 10 diverse dicarboxylic acids | 2018 | LAG/solvent evaporation | Multicomponent salt/multicomponent salt hydrate/salt cocrystal | [ |
| Tofogliflozin + Sodium acetate or Potassium acetate | 2018 | LAG | Salt cocrystal | [ |
| Flurbiprofen + Proline | 2018 | LAG/in situ Variable Temperature Synchrotron X-ray Diffraction | Chiral cocrystal/cocrystal solvate/stoichiometric cocrystal/cocrystal polymorph | [ |
| Piroxicam + Succinic acid or Methylparaben or Resorcinol | 2019 | LAG | Cocrystal | [ |
| Lamotrigine + Phthalimide or Succinimide | 2019 | LAG/slow evaporation/Ternary phase diagram | Cocrystal/Cocrystal hydrate | [ |
| Pyrazinamide + Pimelic acid | 2019 | NG/LAG/Time Resolved In situ Powder X-ray Diffraction | Cocrystal polymorph | [ |
| Nevirapine + | 2019 | NG/LAG | Cocrystal | [ |
| Luteolin (NP) + Isoniazid or Caffeine | 2019 | LAG/Rapid solvent removal | Cocrystal | [ |
| Meloxicam + Salicylic acid or Fumaric acid or Malic acid | 2019 | LAG | Cocrystal | [ |
| Oxcarbazepine + Oxalic acid or 2,5-Dihydroxybenzoic acid or Salicylic acid | 2019 | LAG/slow evaporation | Cocrystal | [ |
| α-D-Glucose + NaCl or NaBr or NaI | 2019 | NG/LAG | Ionic cocrystal | [ |
| Carbamazepine + DL-Mandelic acid or DL-Tartaric acid | 2019 | LAG/computational prediction | Cocrystal/cocrystal polymorph | [ |
| 2-Pyridine-carboxaldehyde benzoylhydrazone (hydrazone) + Malonic acid + Succinic acid + Glutaric acid + Mesaconic acid | 2019 | NG/LAG/slow evaporation | Cocrystal/cocrystal solvate/multicomponent salt | [ |
| Betulin + Adipic acid or Succinic acid or Suberic acid | 2019 | LAG | Cocrystal | [ |
| Ciprofloxacin + Salicylic acid | 2019 | LAG/in situ Raman spectroscopy experiments | Multicomponent salt/multicomponent salt hydrate and solvate/salt-cocrystal | [ |
| Pyrazinamide + Glutaric acid + Isonicotinamide and Pyrazin-2-carboxylic acid + Glutaric acid + Isonicotinamide | 2019 | LAG/In situ Powder X-ray Diffraction | Ternary cocristal | [ |
| Pirfenidone + Fumaric acid or Trimesic acid | 2019 | LAG/slow evaporation | Cocrystal | [ |
| Glipizide + Glutaric acid | 2019 | NG/LAG/slow evaporation/slurry method | Cocrystal | [ |
| Gemfibrozil + Isonicotinamide | 2019 | Milling | Cocrystal | [ |
| Salicylic acid + diverse Imidazole coformers | 2019 | NG/structures were solved by powder X-ray diffraction | Multicomponent salt | [ |
| Caffeine + Glutaric acid | 2020 | NG/LAG/POLAG | Cocrystal | [ |
| Oxyresveratrol + Nicotinamide or Proline | 2020 | LAG/employing principal component analysis | Cocrystal | [ |
| Itraconazole + Terephtalic acid | 2020 | LAG | Cocrystal | [ |
| Ciprofloxacin + Nicotinic acid or Isonicotinic acid | 2020 | LAG | Cocrystal | [ |
| Nicotinamide + Adipic acid | 2020 | Ball-milling LAG/Demonstration of reversible mechanochemical cocrystal polymorph interconversion (stable → metastable phase transformation). This process can be controlled by the choice of milling assembly/Real-time X-ray powder diffraction | Cocrystal polymorph | [ |
| Betulin + Terephthalic acid | 2020 | LAG | Cocrystal | [ |
| Ciprofloxacin + Carvacrol or Thymol | 2020 | NG/ball-milling LAG/slow evaporation/slurry method | Cocrystal | [ |
| 5-Fluorouracil + Kaempferol | 2020 | LAG/slurry method/slow evaporation/ternary phase diagram | Multidrug cocrystal | [ |
| Chromotropic acid + 1,10-Phenanthroline | 2020 | LAG/solvent evaporation | Cocrystal salt hydrate | [ |
| Ibuprofen + Nicotinamide | 2020 | Ball-milling NG/melting/slow evaporation. Detection of cocrystal polymorphism (2 forms). Formation of one or another polymorph depend on the synthetic method used. | Cocrystal polymorph | [ |
| Thiobarbituric acid or Barbituric acid + 1-Hydroxy-4,5-Dimethyl-Imidazole 3-Oxide | 2020 | LAG/solvent evaporation | Cocrystal | [ |
| Telmisartan + Hydroclorothiazide | 2020 | LAG/slow evaporation | Multidrug cocrystal | [ |
| Chlorothiazide + 13 diverse coformers | 2020 | Ball-milling LAG/Study of the effect of grinding on 11 cocrystals an one salt in the presence of the excipients polyvinylpyrrolidone and microcrystalline cellulose | Cocrystal/multicomponent drug | [ |
| Nebivolol hydrochloride + 4-Hydroxybenzoic acid or Nicotinamide | 2020 | LAG | Cocrystal | [ |
| 9-Ethyladenine + Malonic acid or Succinic acid or Fumaric acid or Glutaric acid or Adipic acid | 2020 | LAG/slow evaporation | Cocrystal/multicomponent salt | [ |
| Carbamazepine + DL-Tartaric acid | 2020 | LAG | Cocrystal | [ |
| Emtricitabine + 1,2-Bis(4-pyridyl)ethane or 1,2-Bis(4-pyridyl)ethylene or 4,4′-Azopyridine or 4,4′-Bipyridine | 2020 | LAG | Cocrystal | [ |
| Caffeine + Glutaric acid | 2020 | NG/LAG/POLAG/in situ X-ray powder diffraction | Cocrystal | [ |
| Cocrystal (Barbituric acid/Thiobarbituric acid) BA0.5TBA0.5 + 1-Hydroxy-4,5-dimethyl-imidazole 3-oxide | 2020 | Ball-milling LAG/Preparation of ternary cocrystal system beginning from binary cocrystal system. Evaluation of the possible pathways involved, the evidence suggests a non-concerted process. | Binary and ternary cocrystal | [ |
| Tinidazol + | 2020 | NG/LAG | Cocrystal | [ |
| Ciprofloxacin + Pyrazinoic acid or | 2020 | NG/LAG | Cocrystal | [ |
| Zaltoprofen + Nicotinamide (1:1 or 1:2) | 2020 | LAG | Cocrystal | [ |
| Metronidazole + 3,5-Dihydroxybenzoic or 3,4,5-Trihydroxybenzoic acid | 2020 | LAG/melt/slow evaporation | Cocrystal | [ |
| Exemestane + 9-Hydroxyphenanthrene and 1-Hydroxypyrene | 2020 | LAG | Cocrystal | [ |
| Penciclovir + 3,5-Dihydroxybenzoic acid or Gallic acid (1:1 or 1:1:1 hydrate) or 4-Hydroxycinnamic acid (1:1 or 1:1:1 hydrate) | 2020 | LAG | Cocrystal/cocrystal hydrate | [ |
| Berberine chloride + Pyromellitic dianhydride | 2020 | LAG | Diverse multicomponent stoichiomorphs: multicomponent salt/multicomponent salt polymorph/ionic cocrystal hydrate | [ |
| Allopurinol + Isonicotinamide or Piperazine or 2,4-Dihydroxybenzoic acid | 2020 | LAG/slurry methods/slow evaporation | Cocrystal | [ |
| Trimethoprim + Flufenamic acid or Tolfenamic acid or Mefenamic acid and Sulfamethazine + Flufenamic acid or Niflumic acid | 2020 | LAG/slow evaporation | Multicomponent salt hydrate/multidrug cocrystal | [ |
| Ciprofloxacin + 4-Hydroxybenzoic acid or 4-Aminobenzoic acid or Gallic acid | 2020 | LAG | Multicomponent salt hydrate | [ |
| Regorafenib + Malonic acid or Glutaric acid or Pimelic acid | 2021 | LAG/slurry methods | Cocrystal | [ |
| Theobromine + Trimesic acid or Hemimellitic acid and Caffeine + Trimesic acid or Hemimellitic acid | 2021 | NG/LAG/slow evaporation | Cocrystal/multicomponent salt/cocrystal hydrate | [ |
| Temozolomide + Hesperetin | 2021 | LAG/slurry methods/slow evaporation | Multidrug cocrystal | [ |